Navigation Links
Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis

in, diarrhea, abdominal pain, stomatitis and mouth ulceration, nausea, hepatic enzymes increased, rash, dermatitis and eczema, pruritus, hair loss, musculoskeletal pain, pyrexia, fatigue (including asthenia and malaise).

About HUMIRA

HUMIRA is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS, an arthritis of the spine) and Crohn's disease in the U.S. and Europe. HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), a protein that when produced in excess, plays a central role in the inflammatory responses of immune-mediated diseases. To date, HUMIRA has been approved in 67 countries with more than 190,000 people worldwide currently treated with HUMIRA. Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.

In Europe, HUMIRA, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active RA in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX has been inadequate, and for the treatment of severe, active and progressive RA in adults not previously treated with MTX. HUMIRA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. HUMIRA has been shown to reduce the rate of progression of joint damage as measured byx-ray and to improve physical function, when given in combination with MTX. Additionally, HUMIRA is indicated for the treatment of active and progressive PsA in adults when the response to previous DMARD-therapy has been inadequate and for the treatment of severe, active AS in adults who have had an inadequate response to conventional therapy.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
4. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
5. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
6. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
Post Your Comments:
(Date:8/19/2008)...EGO, Aug. 19 /- Vical Incor...h collaboration with the Karolinska,Institute, a l...h Institute,for Infectious Disease Control (SMI), ...Vaxfectin(R) adjuvant with the Biojector(R) 2000,n...ologies Inc.,OTCBB:BJCT) for a multivalent preven...
(Date:8/18/2008)...findings offer hope for increased life expectancy ...8 /PRNewswire-USNewswire/ -- In the world of Down,... progress has been,tracked for the past 16 years, ... life expectancy of a person with Down syndrome, c...n ,Mr. C, was born. Further, ,Mr. C, does,not exhi...
(Date:8/18/2008)... - Clinical trial currently in Phase I -, .../ -- Tobira,Therapeutics Inc., a clinical stage bi...product discovery against life-threatening and lif...e issuance of Patent No. 7,371,772,B2 by the U.S. ...BR-652, a,CCR5 antagonist currently in Phase I dev...
(Date:8/14/2008)...ORE, Aug. 15 /- AstraZeneca...artnership with the National Cancer,Centre Singapo...H) to,develop anti-cancer compounds. The collabora...tanding (MOU) that was signed today, aims to furth...es in Asia and ultimately,speed up access to new m...
Breaking Medicine Technology:Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 2Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Software Techniques Inc Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time 26 Attendance Solutions 1357 1Software Techniques Inc Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time 26 Attendance Solutions 1357 2High Q NIST nanowires may be practical oscillators 1973 1High Q NIST nanowires may be practical oscillators 1973 2Will Rogers Institute to Honor Worlds Leading Geneticist and Recent Medal of Freedom Recipient Dr Francis S Collins For His Outstanding Contributio 7061 1Will Rogers Institute to Honor Worlds Leading Geneticist and Recent Medal of Freedom Recipient Dr Francis S Collins For His Outstanding Contributio 7061 2Viramontes to Lead PPD Clinical Operations in Mexico Central America and the Caribbean 1971 1Viramontes to Lead PPD Clinical Operations in Mexico Central America and the Caribbean 1971 2Viramontes to Lead PPD Clinical Operations in Mexico Central America and the Caribbean 1971 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
... has offered invaluable advice to women of childbe...ultivitamin daily, to cut the risks of delivering ...has indicated that by being regular with intake of...ny severe birth defects can be offset. The defects...
...dents are unprepared for skilled prescribing, warn...ribing in the UK is abundant, write Jeffrey Aronso... underprescribed and prescription errors are commo...ork in hospitals. The reasons for these errors a...
...etes in pregnancy has increased four times among A...cerns that gestational diabetes// may cause proble...ent in the last five years. Diabetes Australia NSW...a dangerous precedent. "In just five years we hav...
...University of South Florida College of Medicine sa... Florida is discouraging medical students// from o...alization. The situation means that many people do...Deutsch, MD, lead author of the study and chief re...
Other Medicine News:Health News:Many Medical Students Unprepared for Skilled Prescribing 2Health News:Malpractice Worry Discouraging Medical Students From Taking Up Obstetrics And Gynecology 2
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int
The D185 is the only stimulator with FDA clearance for this application. The D185 allows transcranial motor evoked potentials to be used in surgical procedures such as scoliosis correction, spinal tu
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool.
The Wilson Plus Radiolucent Wilson Frame delivers unrestricted radiolucency and C-arm integration with a convenient and stable method of maintaining patients in a flexed position for laminectomy, dec
Medicine Products: